In this article

What is the early phase of GLP-1 therapy?

The early phase (commonly the first ~16 weeks) refers to the period of dose escalation and physiological adaptation to GLP-1 receptor agonists (such as semaglutide, liraglutide, or tirzepatide).

During this phase, the body is adjusting to:

  • Slower gastric emptying
  • Reduced appetite and caloric intake
  • Changes in hydration and electrolyte balance
  • Rapid metabolic shifts

This makes it the most dynamic phase of treatment, where both tolerance and early metabolic response need to be monitored closely.

Why monitoring is different in this phase

While both early and later phases rely on biomarkers, the type and purpose of monitoring differ.

In the early phase:

  • Biomarkers are used to detect acute physiological stress and tolerance issues
  • Changes can occur rapidly and non-linearly
  • Symptom context is still important for interpretation

Which biomarkers matter most early on

1. Electrolytes and hydration markers

Reduced food and fluid intake can quickly affect:

  • Total Protein
  • Kidney function markers (e.g., creatinine trends)

These help detect early dehydration or imbalance.

2. Liver enzymes and metabolic stress

Rapid weight loss and metabolic shifts may transiently affect:

  • ALT / AST
  • Markers associated with liver fat mobilization

3. Lipid profile (especially triglycerides)

Triglycerides are particularly important early on:

  • Elevated levels increase pancreatitis risk
  • Rapid metabolic changes may initially destabilize lipid levels

4. Glycemic markers

GLP-1 therapy rapidly affects glucose regulation:

  • % HbA1c
  • C-Peptide

These help assess early metabolic response and detect excessive drops in intake or imbalance.

5. Nutritional status indicators (early trends)

Even early in treatment, reduced intake may begin to impact:

  • Ferritin
  • Vitamin D

What symptoms still play a role

Although this is a biomarker-driven phase, symptoms provide essential context for interpreting early changes.

Important symptoms include:

  • Persistent nausea or vomiting
  • Inability to maintain hydration
  • Abdominal pain (especially severe or radiating)
  • Dizziness or weakness
  • Right upper abdominal discomfort (gallbladder-related)

Symptoms help determine whether biomarker changes reflect:

  • Normal adaptation

    or

  • Emerging intolerance or risk

Key risks in the early phase

  • Gastrointestinal intolerance: driven by delayed gastric emptying and central appetite effects.
  • Dehydration and electrolyte imbalance: often due to reduced intake rather than direct drug effect.
  • Under-eating and rapid caloric deficit: can begin affecting metabolic stability and lean mass early.
  • Gallbladder stress: triggered by rapid weight loss and fat mobilization, rather than routine enzyme screening alone

How to support your body during this phase

  • Maintain hydration: fluid intake should be intentional, not appetite-driven.
  • Prioritize protein and nutrient density: even small meals should be nutritionally meaningful.
  • Monitor both labs and symptoms together: neither should be interpreted in isolation.
  • Avoid aggressive dose escalation: tolerance should guide progression.

How often should you monitor

Because this phase is dynamic:

  • Monthly biomarker monitoring during the first 16 weeks
  • Ongoing symptom tracking for context
  • Additional testing if abnormalities or symptoms arise

Key takeaway

The early phase of GLP-1 therapy is about safe adaptation.

It remains biomarker-driven, but focuses on short-term physiological stability, tolerance, and early metabolic shifts, rather than long-term optimization.

Where can I read more?

GLP-1 analog therapy and hemoglobin levels: Insights from a retrospective study โ€“ PMC

https://www.healthline.com/health/drugs/ozempic-blood-test

https://www.mayoclinic.org/drugs-supplements/teriparatide-subcutaneous-route/description/drg-20066280